{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:03:57Z","timestamp":1785215037090,"version":"3.55.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105307","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:59:09Z","timestamp":1774972749000},"page":"105307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications"],"prefix":"10.1016","volume":"223","author":[{"given":"G.","family":"Gentile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gelibter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"De Marchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pappalardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Botticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mazzuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Siringo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2026.105307_bib1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105307_bib2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.pathol.2016.03.005","article-title":"Loss of expression of BAP1 is very rare in non-small cell lung carcinoma","volume":"48","author":"Andrici","year":"2016","journal-title":"Pathology"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105307_bib3","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.3390\/cancers15194733","article-title":"Clinical characteristics, response to platinum-based chemotherapy and poly (Adenosine Phosphate-Ribose) polymerase inhibitors in advanced lung cancer patients harboring BRCA mutations","volume":"15","author":"Arnon","year":"2023","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105307_bib4","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/hmg\/ddm127","article-title":"Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study","volume":"16","author":"Brennan","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.critrevonc.2026.105307_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"Chia","year":"2014","journal-title":"Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105307_bib6","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1186\/s12967-024-05538-4","article-title":"Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional\/prospective study design (FAHIC: Lung)","volume":"22","author":"Citarella","year":"2024","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105307_bib7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/carcin\/bgn044","article-title":"Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers","volume":"29","author":"Cybulski","year":"2008","journal-title":"Carcinogenesis"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105307_bib8","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.3390\/cancers14174233","article-title":"Whole-exome sequencing identifies pathogenic germline variants in patients with lynch-like syndrome","volume":"14","author":"Dos Santos","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105307_bib9","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/1078-0432.CCR-18-2660","article-title":"Rare, pathogenic germline variants in fanconi anemia genes increase risk for squamous lung cancer","volume":"25","author":"Esai Selvan","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105307_bib10","first-page":"1871","article-title":"Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk","volume":"15","author":"Esai Selvan","year":"2020","journal-title":"J. Thoracic Oncol. Off. Pub. Int. Assoc. Study Lung Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105307_bib11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jtho.2023.05.028","article-title":"The role of germline mutations in thoracic malignancies: between myth and reality","volume":"18","author":"Farinea","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"maggio","key":"10.1016\/j.critrevonc.2026.105307_bib12","article-title":"Familial rare EGFR-mutant lung cancer syndrome: review of literature and description of R776H family","volume":"191","author":"Gabriel","year":"2024","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105307_bib13","first-page":"456","article-title":"Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations","volume":"9","author":"Gazdar","year":"2014","journal-title":"J. Thoracic Oncolo. Off. Pub. Int. Assoc. Study Lung Cancer"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105307_bib14","article-title":"Germline alterations in patients with lung cancer","volume":"S0923-7534","author":"Govindan","year":"2025","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105307_bib15","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1158\/1078-0432.CCR-22-0791","article-title":"FOXM1 variant contributes to gefitinib resistance via activating Wnt\/\u03b2-catenin signal pathway in patients with non-small cell lung cancer","volume":"28","author":"Guan","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105307_bib16","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/1078-0432.CCR-23-2357","article-title":"Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in patients with non-small cell lung cancer","volume":"30","author":"Guan","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105307_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105307_bib18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"agosto","key":"10.1016\/j.critrevonc.2026.105307_bib19","article-title":"Somatic and germline ATM variants in non-small-cell lung cancer: therapeutic implications","volume":"188","author":"Hernandez-Martinez","year":"2023","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105307_bib20","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1158\/1078-0432.CCR-17-1745","article-title":"Discrimination of germline EGFR T790M mutations in plasma cell-free DNA allows study of prevalence across 31,414 cancer patients","volume":"23","author":"Hu","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.20892\/j.issn.2095-3941.2018.0506","article-title":"Prevalence and clinical significance of pathogenic germline BRCA1\/2 mutations in chinese non-small cell lung cancer patients","volume":"16","author":"Hu","year":"2019","journal-title":"Cancer Biol. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00439-003-0968-7","article-title":"Lung cancer risk in germline P53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk","volume":"113","author":"Hwang","year":"2003","journal-title":"Hum. Genet."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105307_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.21933","article-title":"Contribution of germline mutations to PARK2 gene inactivation in lung adenocarcinoma","volume":"51","author":"Iwakawa","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105307_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbrc.2019.11.050","article-title":"Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors","volume":"522","author":"Ji","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105307_bib25","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/j.jtho.2018.08.365","article-title":"MA06.10 germline mutation in ATM affect lung cancer risk with high effect","volume":"13","author":"Ji","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105307_bib26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov."},{"issue":"giug","key":"10.1016\/j.critrevonc.2026.105307_bib27","article-title":"Prevalence of pathogenic germline variants in a cohort of patients with early onset non-small cell lung cancer (EOLUNG)","volume":"41","author":"Jove","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105307_bib28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/antiox11010114","article-title":"BAP1 downregulates NRF2 target genes and exerts anti-tumorigenic effects by deubiquitinating KEAP1 in lung adenocarcinoma","volume":"11","author":"Kang","year":"2022","journal-title":"Antioxidants"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib29","article-title":"BRCA1 expression and outcome in patients with EGFR-mutant NSCLC treated with gefitinib alone or in combination with olaparib","volume":"2","author":"Karachaliou","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105307_bib30","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.21037\/tlcr.2019.11.24","article-title":"BAP1: role in carcinogenesis and clinical implications","volume":"9","author":"Kobrinski","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","article-title":"Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO precision medicine working group recommendations","volume":"34","author":"Kuzbari","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105307_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115571","article-title":"Prevalence and characteristics of lung cancer in families harboring pathogenic germline variants in cancer predisposing genes: a 20-year retrospective analysis","author":"Laguna","year":"2025","journal-title":"European Journal Cancer 0 (0"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105307_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-022-06723-z","article-title":"Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis","volume":"196","author":"Laitman","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00432-018-2817-z","article-title":"TP53 mutations as potential prognostic markers for specific cancers: analysis of data from the cancer genome atlas and the international agency for research on cancer TP53 database","volume":"145","author":"Li","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105307_bib35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.bjc.6601030","article-title":"Further observations on LKB1\/STK11 status and cancer risk in Peutz-Jeghers syndrome","volume":"89","author":"Lim","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105307_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.774156","article-title":"Identification of the unique clinical and genetic features of chinese lung cancer patients with EGFR germline mutations in a large-scale retrospective study","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105307_bib37","first-page":"1091","article-title":"Family history and lung cancer risk: international multicentre case-control study in eastern and central europe and meta-analyses","volume":"21","author":"Lissowska","year":"2010","journal-title":"Cancer Causes Control CCC"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105307_bib38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3892\/ol.2023.13868","article-title":"Germline EGFR mutations in lung cancer (Review)","volume":"26","author":"Liu","year":"2023","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105307_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3892\/ol.2023.13868","article-title":"Germline EGFR mutations in lung cancer (Review)","volume":"26","author":"Liu","year":"2023","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105307_bib40","first-page":"732","article-title":"EGFR and ERBB2 germline mutations in Chinese lung cancer patients and their roles in genetic susceptibility to cancer","volume":"14","author":"Lu","year":"2019","journal-title":"J. Thoracic Oncolo. Off. Pub. Int. Assoc. Study Lung Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105307_bib41","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs Guideline-based germline testing","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105307_bib42","first-page":"1377","article-title":"V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors","volume":"9","author":"Matsushima","year":"2014","journal-title":"J. Thoracic Oncolo. Off. Pub. Int. Assoc. Study Lung Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105307_bib43","article-title":"High prevalence of somatic oncogenic driver alterations in patients with NSCLC and Li-Fraumeni syndrome","volume":"15","author":"Mezquita","year":"2020","journal-title":"J. Thoracic Oncolo. Off. Pub. Int. Assoc. Study Lung Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105307_bib44","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105307_bib45","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105307_bib46","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105307_bib47","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1158\/1055-9965.EPI-21-1287","article-title":"Germline pathogenic variants impact clinicopathology of advanced lung cancer","volume":"31","author":"Mukherjee","year":"2022","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological Guidance for Systematic Reviews of Observational Epidemiological Studies Reporting Prevalence and Cumulative Incidence Data","volume":"13","author":"Munn","year":"2015","journal-title":"Int. J. Evid. -Based Healthc."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105307_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021611","article-title":"Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis","volume":"8","author":"O\u2019Keeffe","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.critrevonc.2026.105307_bib50","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ Clin. Res. Ed."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105307_bib51","first-page":"1438","article-title":"Mutational characteristics and clinical outcomes for lung adenocarcinoma With EGFR germline mutations","volume":"19","author":"Pan","year":"2024","journal-title":"J. Thoracic Oncolo. Off. Pub. Int. Assoc. Study Lung Cancer"},{"issue":"luglio","key":"10.1016\/j.critrevonc.2026.105307_bib52","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2147\/OTT.S272563","article-title":"Current evidence and future perspectives about the role of PARP inhibitors in the treatment of thoracic cancers","volume":"16","author":"Parisi","year":"2023","journal-title":"OncoTargets Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105307_bib53","first-page":"1673","article-title":"Germline mutations in DNA repair genes in lung adenocarcinoma","volume":"12","author":"Parry","year":"2017","journal-title":"J. Thoracic Oncolo. Off. Pub. Int. Assoc. Study Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105307_bib54","article-title":"Revisiting variation in the somatic mutation landscape of non-small cell lung cancer","volume":"6","author":"Pathak","year":"2025","journal-title":"Hum. Genet. Genom. Adv."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105307_bib55","first-page":"1364","article-title":"Familial lung cancers caused by EGFR germline mutations: the frequency is probably underestimated but specific genotypic features and some particular disease characteristics should help their screening","volume":"19","author":"Pujol","year":"2024","journal-title":"J. Thoracic Oncolo. Off. Pub. Int. Assoc. Study Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105307_bib56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.lungcan.2008.10.029","article-title":"Familial lung cancer risk among women in Poland","volume":"65","author":"Rachtan","year":"2009","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105307_bib57","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/cancers14051321","article-title":"Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance","volume":"14","author":"Reita","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib58","article-title":"Somatic and germline BRCA 1 and 2 mutations in advanced NSCLC from the SAFIR02-lung trial","volume":"1","author":"Remon","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"issue":"embre","key":"10.1016\/j.critrevonc.2026.105307_bib59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2022.09.002","article-title":"Characterization of lung cancers in patients with BRCA germline variants: a multicenter series","volume":"173","author":"Sanchis-Borja","year":"2022","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105307_bib60","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM deficiency is associated with sensitivity to PARP1- and ATR inhibitors in lung adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105307_bib61","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/s12885-016-2670-x","article-title":"BRCA1-associated protein 1 deficiency in lung adenocarcinoma predicts poor outcome and increased tumor invasion","volume":"16","author":"Shen","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105307_bib62","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.resinv.2018.12.005","article-title":"Germline mutations in lung cancer","volume":"57","author":"Shukuya","year":"2019","journal-title":"Respir. Investig."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105307_bib64","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10689-024-00418-8","article-title":"A dual biomarker in non-small cell lung cancer that predicts Li Fraumeni syndrome: lung cancer and Li Fraumeni","volume":"23","author":"Sorscher","year":"2024","journal-title":"Fam. Cancer"},{"issue":"settembre","key":"10.1016\/j.critrevonc.2026.105307_bib65","article-title":"Rate of pathogenic germline variants in patients with lung cancer","volume":"7","author":"Sorscher","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105307_bib66","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fonc.2019.00550","article-title":"Identification of germline mismatch repair gene mutations in lung cancer patients with paired tumor-normal next generation sequencing: a retrospective study","volume":"9","author":"Sun","year":"2019","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib67","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib68","doi-asserted-by":"crossref","first-page":"699","DOI":"10.21037\/tlcr-23-853","article-title":"ATM-the gene at the moment in non-small cell lung cancer","volume":"13","author":"Thu","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105307_bib69","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jgg.2021.12.012","article-title":"Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients","volume":"49","author":"Tian","year":"2022","journal-title":"J. Genet. Genom. = Yi Chuan Xue Bao"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105307_bib70","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00558","article-title":"Association of germline pathogenic variants in MUTYH and other DNA damage response genes with lung cancer risk among non-hispanic Whites and African Americans","author":"Trendowski","year":"2025","journal-title":"JCO Precis Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105307_bib71","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1200\/JCO.24.00662","article-title":"Selection of germline genetic testing panels in patients with cancer: ASCO guideline","volume":"42","author":"Tung","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105307_bib72","doi-asserted-by":"crossref","first-page":"466","DOI":"10.5507\/bp.2015.029","article-title":"Comparison of the prevalence of KRAS-LCS6 polymorphism (Rs61764370) within different tumour types (Colorectal, Breast, Non-Small Cell Lung Cancer and Brain Tumours). A study of the Czech population","volume":"159","author":"Uvirova","year":"2015","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czechoslov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105307_bib73","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz095","article-title":"Germline testing for patients with BRCA1\/2 mutations on somatic tumor testing","volume":"4","author":"Vlessis","year":"2020","journal-title":"JNCI Cancer Spectr."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105307_bib74","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ccell.2022.08.013","article-title":"Analyses of rare predisposing variants of lung cancer in 6,004 whole genomes in Chinese","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105307_bib75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13053-021-00174-1","article-title":"Characteristics of BRCA1\/2 pathogenic germline mutations in chinese NSCLC patients and a comparison with HBOC","volume":"19","author":"Xu","year":"2021","journal-title":"Hered. Cancer Clin. Pract."},{"key":"10.1016\/j.critrevonc.2026.105307_bib76","article-title":"Profiling oncogenic germline mutations in unselected Chinese lung cancer patients","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105307_bib77","article-title":"Profiling oncogenic germline mutations in unselected Chinese lung cancer patients","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105307_bib78","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105307_bib79","article-title":"A high percentage of NSCLC with germline CHEK2 mutation harbors actionable driver alterations: survey of a cancer genomic database and review of literature","volume":"3","author":"Zhang","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105307_bib80","first-page":"901","article-title":"A germ-line P53 mutation accelerates pulmonary tumorigenesis: P53-independent efficacy of chemopreventive agents green tea or dexamethasone\/myo-inositol and chemotherapeutic agents taxol or adriamycin","volume":"60","author":"Zhang","year":"2000","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105307_bib81","first-page":"901","article-title":"A germ-line P53 mutation accelerates pulmonary tumorigenesis: P53-independent efficacy of chemopreventive agents green tea or dexamethasone\/myo-inositol and chemotherapeutic agents taxol or adriamycin","volume":"60","author":"Zhang","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105307_bib82","article-title":"Investigation of PALB2 mutation and correlation with immunotherapy biomarker in Chinese non-small cell lung cancer patients","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"issue":"aprile","key":"10.1016\/j.critrevonc.2026.105307_bib83","article-title":"Diagnostic and therapeutic ER\u03b2, HER2, BRCA biomakers in the histological subtypes of lung adenocarcinoma according to the IASLC\/ATS\/ERS classification","volume":"51","author":"Zhong","year":"2021","journal-title":"Ann. Diagn. Pathol."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105307_bib84","article-title":"Germline mutation analysis and real-world impact in a selected cohort of patients with non-small cell lung cancer: INHERITY LC study","volume":"S1525-7304","author":"Zurera","year":"2025","journal-title":"Clin. Lung Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:05:59Z","timestamp":1780038359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":84,"alternative-id":["S1040842826001940"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105307","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105307"}}